FDA Approves BAQSIMI, The First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia

From asweetlife.org

The U.S. Food and Drug Administration (FDA) has approved Lilly’s BAQSIMI (glucagon) nasal powder 3 mg for the treatment of severe hypoglycaemia in people with diabetes ages four years and above. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycaemia rescue in mind.

Severe hypoglycaemia is a serious medical condition that constitutes an emergency for people with type 1 and type 2 diabetes. It is characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. If untreated, severe hypoglycaemia can lead to serious consequences, such as loss of consciousness, seizure, coma and death.

BAQSIMI is a portable, dry nasal spray form of glucagon, ready to use with no reconstitution or priming required in a single, fixed 3 mg dose. It is absorbed in the nose, so does not require inhalation. BAQSIMI does not need to be refrigerated and can be stored at temperatures up to 86°F/30°C in the shrink-wrapped tube provided.

Acquired by Lilly from Locemia Solutions in 2015, BAQSIMI is a new formulation of rescue glucagon. Dr. Claude Piche, CEO and co-founder of Locemia Solutions, credits co-founder Robert Oringer as the original inspiration behind BAQSIMI. Oringer has two sons diagnosed with type 1 diabetes. 

https://asweetlife.org/fda-approves-baqsimi-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia/?utm_source=ASweetLife.org+List&utm_campaign=5f486e196b-ASweetLife+Weekly+Update++-+Nov.+14%2C+2017_COPY_01&utm_medium=email&utm_term=0_5125b14cf8-5f486e196b-413392997